Search results for "Sida"

showing 10 items of 1584 documents

Phenotype determining alleles in GM1 gangliosidosis patients bearing novel GLB1 mutations.

2010

Hofer D, Paul K, Fantur K, Beck M, Roubergue A, Vellodi A, Poorthuis BJ, Michelakakis H, Plecko B, Paschke E. Phenotype determining alleles in GM1 gangliosidosis patients bearing novel GLB1 mutations. GM1 gangliosidosis manifests with progressive psychomotor deterioration and dysostosis of infantile, juvenile, or adult onset, caused by alterations in the structural gene coding for lysosomal acid s-galactosidase (GLB1). In addition, allelic variants of this gene can result in Morquio B disease (MBD), a phenotype with dysostosis multiplex and entire lack of neurologic involvement. More than 100 sequence alterations in the GLB1 gene have been identified so far, but only few could be proven to …

AdolescentGenotypeNonsense mutationBlotting WesternDNA Mutational AnalysisBiologymedicine.disease_causeCell LineGenotypeChlorocebus aethiopsGeneticsmedicineMissense mutationAnimalsHumansAlleleChildGenetics (clinical)AllelesGeneticsMutationGangliosidosis GM1DysostosisInfantmedicine.diseasebeta-GalactosidasePhenotypePhenotypeGLB1Child PreschoolCOS CellsMutationClinical genetics
researchProduct

Acogimiento familiar: estudio de las interacciones ante las visitas familiares

1999

La ley orgánica 1/96 sobre Protección Jurídica del niño, establece una medida de protección denominada acogimiento familiar preadoptivo, en aquellos supuestos en donde se valora como irreversible el retorno a la familia de origen del niño, y en donde se dispone de una familia alternativa para la integración social de los niños. La regulación del régimen de visitas compete, en primer lugar, a la administración responsable de la protección a la infancia y, en segundo lugar, a la Fiscalía de Menores, quien a través del Juzgado de Familia podrá regular judicialmente el régimen de visitas. El desarrollo de estas visitas y su plasmación en actos concretos está mediatizado por la complejidad de la…

AdopciónHealth (social science)Sociology and Political ScienceIntegración socialSidaTutelaInteracción padres e hijosSocial SciencesTreball social amb els infantsAcolliment familiarHEmocionesProtecciónRégimen de visitasAcogimiento familiarReacciones físicasSocializaciónDesamparoRetornoSocial Sciences (miscellaneous)
researchProduct

[Fabry disease in Italy: first epidemiologic and collaborative study].

2005

The authors sought to define the prevalence of Fabry disease and to establish the incidence and its natural history in Italy. The aim of this study was to point out the first clinical signs and symptoms to perform an early diagnosis and hence to start a specific therapeutic treatment. Fabry disease is an inborn error of metabolism caused by the deficiency of the lysosomal enzyme alpha-galactosidase A. Fabry disease is a severe X-linked disorder presenting with a higher morbidity between the third and the fourth decade of life. Fabry disease may be confused with other diseases or completely misdiagnosed: its frequency is estimated worldwide to be 1:117000. In Italy, 65 patients have been ide…

AdultDiagnosis DifferentialMaleAdolescentItalyalpha-GalactosidaseFabry DiseaseHumansFemaleAlgorithms
researchProduct

Human herpesvirus type 8 DNA sequences in biological samples of HIV-positive and negative individuals in Sicily.

1997

Objective: To evaluate the circulation of a new human herpesvirus (HHV), HHV-8 or Kaposi's sarcoma (KS)-associated herpesvirus in a geographical area where a high incidence rate of classical KS was already present before the appearance of the AIDS epidemic. Design and methods: The study was carried out by analysing: (i) bioptic samples from classic, AIDS-associated KS, and controls; (ii) peripheral blood mononuclear cells (PBMC) from classic KS, HIV-positive subjects with and without KS and healthy HIV-negative individuals; (iii) semen samples from heterosexual HIV-positive and HIV-negative individuals affected or not by KS; and (iv) cervical swabs from HIV-negative healthy heterosexual fem…

AdultImmunologyPopulationSemenHIV InfectionsBiologymedicine.disease_causeHerpesviridaeViruslaw.inventionlawmedicineImmunology and AllergyHumanseducationSidaSicilyPolymerase chain reactioneducation.field_of_studyAIDS-Related Opportunistic Infectionsvirus diseasesHerpesviridae InfectionsMiddle Agedbiology.organism_classificationVirologyInfectious DiseasesImmunologyDNA ViralHerpesvirus 8 HumanHIV-1Viral diseaseViral loadAIDS (London, England)
researchProduct

Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before an…

2020

Rossella Parini,1,2 Guillem Pintos-Morell,3 Julia B Hennermann,4 Ting-Rong Hsu,5 Nesrin Karabul,6 Vasiliki Kalampoki,7 Andrey Gurevich,7 Uma Ramaswami8 On behalf of the FOS Study Group1Rare Metabolic Diseases Unit, MBBM Foundation, San Gerardo Hospital, Reference Centre for Hereditary Metabolic Disorders (MetabERN), Monza, Italy; 2TIGET Institute, IRCCS San Raffaele Hospital, Milan, Italy; 3Division of Rare Diseases, Reference Centre for Hereditary Metabolic Disorders (MetabERN), University Hospital Vall d’Hebron, Autonomous University of Barcelona, Barcelona, Spain; 4Villa Metabolica, Department of Pediatric and Adolescent Medicine, University Medical Center, Mainz, Germany; 5Dep…

AdultMale0301 basic medicinemedicine.medical_specialtyestimated glomerular filtration rateAdolescentPharmaceutical ScienceRenal functionLeft ventricular hypertrophyFabry Outcome SurveyYoung Adult03 medical and health sciences0302 clinical medicineInternal medicineDrug DiscoverymedicineHumansEnzyme Replacement TherapyEstimated glomerular filtration rateChildAgalsidase alfaOriginal ResearchRetrospective StudiesPharmacologyagalsidase alfaFabry diseaseProteinuriaDrug Design Development and Therapybusiness.industryLeft ventricular hypertrophyEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry diseaseRecombinant Proteinsleft ventricular hypertrophyIsoenzymesTreatment Outcome030104 developmental biologyMale patientalpha-Galactosidase030220 oncology & carcinogenesisEnzyme replacement therapyCohortmedicine.symptombusinessAgalsidase alfa
researchProduct

Mutation analyses in 17 patients with deficiency in acid β-galactosidase: three novel point mutations and high correlation of mutation W273L with Mor…

2001

An inherited deficiency in beta-galactosidase can result in GM1 gangliosidosis, with several phenotypes of generalized or chronic psychomotor deterioration, as well as in Morquio disease type B, a characteristic mucopolysaccharidosis free of neurological symptoms. We performed mutation analyses in 17 juvenile and adult patients from various European regions with a deficiency in beta-galactosidase and skeletal abnormalities. Fifteen of these had the Morquio B phenotype and have remained neurologically healthy until now while the two others exhibited psychomotor retardation of juvenile onset. A two-base substitution (851-852TG--CT; W273L) was present in 14 of the 15 Morquio B cases. Even if o…

AdultMaleAdolescentMucopolysaccharidosisDNA Mutational AnalysisRestriction MappingMutation MissenseBiologyGeneticsmedicineHumansPoint MutationMissense mutationRNA MessengerChildGenetics (clinical)DNA PrimersGeneticsPsychomotor retardationReverse Transcriptase Polymerase Chain ReactionPoint mutationMucopolysaccharidosis IVHeterozygote advantageMiddle Agedbeta-Galactosidasemedicine.diseasePhenotypePedigreePhenotypeGLB1Child PreschoolMutation (genetic algorithm)Femalemedicine.symptomHuman Genetics
researchProduct

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

2022

AbstractThe STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment of adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes. The co-primary endpoints were the percentage change in body weight and achievement of weight loss of ≥5% at week 104. Efficacy was assessed among all randomized participants regardless of treatment discontinuation or rescue intervention. From 5 October 2018 to 1 February 2019, 304 participants were randomly assigned to semaglutide 2.4 mg (n = 152) or placebo (n = 152), 92.8% of whom completed the trial (attended t…

AdultMaleGlucagon-Like PeptideHypoglycemic AgentObesidadInvestigación médicaGeneral MedicineMiddle AgedOverweightWeight LoGeneral Biochemistry Genetics and Molecular BiologyTratamiento médicoTreatment OutcomeDouble-Blind MethodDiabetes Mellitus Type 2GlucemiaControl glucémicoFemaleObesitySettore MED/49 - Scienze Tecniche Dietetiche ApplicateHuman
researchProduct

Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: The EPIB 2008 study

2010

To compare the management and the virological and serological efficacy of treatments for chronic hepatitis B (CHB) in HIV positive and negative patients.Two hundred and forty-six HIV positive and 205 HIV negative consecutive patients with past or present CHB, seen in October 2008 in participating departments, were included in a multicenter study. All the data were retrospectively collected from the first visit to October 2008 through a standardized questionnaire.Compared to HIV negative patients, HIV positive patients more often presented positive HBeAg (46.4% vs. 32.8%, p=0.01), HBV genotype A (54.8% vs. 17.1%, p0.0001), co-infection with HCV (12.4% vs. 5.9%, p=0.0002) or HDV (12.6% vs. 2.…

AdultMaleHepatitis B virusmedicine.medical_specialtyOrganophosphonatesHIV InfectionsAntiviral AgentsSerologyHepatitis B AntigensHepatitis B ChronicPharmacotherapyAcquired immunodeficiency syndrome (AIDS)Surveys and QuestionnairesInternal medicinemedicineHumansHepatitis B AntibodiesTenofovirSidaRetrospective StudiesHepatologybiologybusiness.industryAdeninevirus diseasesMiddle AgedHepatitis Bbiology.organism_classificationmedicine.diseaseHBeAgLentivirusImmunologyFemaleFranceViral diseasebusinessJournal of Hepatology
researchProduct

Low Trough Plasma Concentrations of Nevirapine Associated with Virologic Rebounds in HIV-Infected Patients Who Switched from Protease Inhibitors

2005

BACKGROUND:The substitution of a nonnucleoside reverse-transcriptase inhibitor (NNRTI) for protease inhibitors (PIs) has demonstrated its suitability to maintain virologic response. However, the switch from PIs to an NNRTI could fail for a number of reasons, including NNRTI-associated toxicity and emergence of NNRTI-resistant variants.OBJECTIVE:To describe the virologic failures among 74 HIV-infected patients who switched from PIs to nevirapine.METHODS:Virologic failure was defined as any rebound of the plasma HIV-RNA (pVL) levels >1000 copies/mL on one occasion or 2 consecutive intermittent viremia episodes defined as increases of the pVL >20 copies/mL but <1000 copies/mL. Virolog…

AdultMaleNevirapineHIV InfectionsViremiaImmunopathologyDrug Resistance ViralHumansMedicinePharmacology (medical)Protease inhibitor (pharmacology)NevirapineProspective StudiesSidabiologyReverse-transcriptase inhibitorbusiness.industryHIV Protease InhibitorsMiddle AgedViral Loadbiology.organism_classificationmedicine.diseaseVirologyToxicityHIV-1FemaleViral diseasebusinessFollow-Up Studiesmedicine.drugAnnals of Pharmacotherapy
researchProduct

Hearing impairment as an early sign of alpha-mannosidosis in children with a mild phenotype: Report of seven new cases.

2019

Alpha-mannosidosis (AM) is a very rare (prevalence: 1/500000 births) autosomal recessive lysosomal storage disorder. It is characterized by multi-systemic involvement associated with progressive intellectual disability, hearing loss, skeletal anomalies, and coarse facial features. The spectrum is wide, from very severe and lethal to a milder phenotype that usually progresses slowly. AM is caused by a deficiency of lysosomal alpha-mannosidase. A diagnosis can be established by measuring the activity of lysosomal alpha-mannosidase in leucocytes and screening for abnormal urinary excretion of mannose-rich oligosaccharides. Genetic confirmation is obtained with the identification of MAN2B1 muta…

AdultMalePediatricsmedicine.medical_specialtyAdolescentHearing lossAlpha-mannosidosisUrinary systemYoung Adultalpha-MannosidaseIntellectual DisabilityIntellectual disabilityExome SequencingGeneticsmedicineHumansChildHearing LossGenetics (clinical)Exome sequencingCoarse facial featuresbusiness.industrySiblingsEnzyme replacement therapymedicine.diseaseHypotoniaPhenotypeChild Preschoolalpha-MannosidosisFemalemedicine.symptombusinessLysosomesAmerican journal of medical genetics. Part A
researchProduct